Quest Diagnostics (DGX) Tops Q4 EPS by 4c; Guides In-Line

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.31, $0.04 better than the analyst estimate of $1.27. Revenue for the quarter came in at $1.86 billion versus the consensus estimate of $1.86 billion.

GUIDANCE:

Quest Diagnostics sees FY2017 EPS of $5.37-$5.52, versus the consensus of $5.45. Quest Diagnostics sees FY2017 revenue of $7.64-7.72 billion, versus the consensus of $7.66 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes
• GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says